127 related articles for article (PubMed ID: 7561498)
1. Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma.
Rubin JS; Wadler S; Beitler JJ; Haynes H; Rozenblit A; McGill F; Goldberg G; Runowicz C
J Laryngol Otol; 1995 Aug; 109(8):744-7. PubMed ID: 7561498
[TBL] [Abstract][Full Text] [Related]
2. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
3. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Church MW; Blakley BW; Burgio DL; Gupta AK
J Assoc Res Otolaryngol; 2004 Sep; 5(3):227-37. PubMed ID: 15185124
[TBL] [Abstract][Full Text] [Related]
4. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
Serkies K; Jassem J
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
[TBL] [Abstract][Full Text] [Related]
5. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial.
Small W;
Semin Oncol; 2003 Dec; 30(6 Suppl 18):68-71. PubMed ID: 14727243
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
7. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
8. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
9. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
Ryu SY; Lee WM; Kim K; Park SI; Kim BJ; Kim MH; Choi SC; Cho CK; Nam BH; Lee ED
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e577-81. PubMed ID: 21840137
[TBL] [Abstract][Full Text] [Related]
11. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
12. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
Paken J; Govender CD; Pillay M; Feyasa M; Sewram V
PLoS One; 2023; 18(4):e0283639. PubMed ID: 37014872
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
15. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma.
Chen WC; Jackson A; Budnick AS; Pfister DG; Kraus DH; Hunt MA; Stambuk H; Levegrun S; Wolden SL
Cancer; 2006 Feb; 106(4):820-9. PubMed ID: 16421885
[TBL] [Abstract][Full Text] [Related]
16. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of hearing in children with solid tumors treated by chemotherapy].
Gryczyńska D; Rychwalska M; Pekacka K; Krawczyński M; Bodalski J
Otolaryngol Pol; 2001; 55(2):179-83. PubMed ID: 11494735
[TBL] [Abstract][Full Text] [Related]
18. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
19. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
[TBL] [Abstract][Full Text] [Related]
20. Potential for use of amifostine in cervical cancer.
Small W
Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]